Specialty Drug Costs Are Eating Your Health Plan Budget in 2026 — Here’s What Actually Stops It

Watch enough primetime TV and you’ll see the pattern: a chronic-condition drug ad, a soothing voiceover, and a list of side effects longer than the actual pitch. Big pharma spends billions putting those ads in front of your employees.

What most employers never see is the other side of that spend. It’s the line item on their own claims report growing faster than almost anything else on the plan. That line item is specialty drugs. And if you sponsor a group health plan for 50 to 1,000 employees, it’s probably the single biggest threat to keeping your renewal flat in 2026.

Here’s the number that should get your attention. In 2025, 5.5% of covered members used at least one specialty drug, up from 4.4% just two years earlier, according to Pharmaceutical Strategies Group’s 2026 Artemetrx State of Specialty Spend and Trend Report, built on 204 million medical claims and 48 million pharmacy claims. That’s roughly one in eighteen of your people. They drive about half of your pharmacy spend.

And here’s the part that separates a real analysis from a renewal presentation: the growth isn’t coming from price increases. In PSG’s 2025 data, specialty trend ran 10.8% gross. Utilization accounted for 10.6 of those points. Unit cost accounted for 0.1.

It isn’t that specialty drugs got more expensive. It’s that more of your people are on them. The math gets worse before a single new blockbuster reaches the market.

The good news: this is one of the few cost problems on your plan where a mid-sized employer has real, specific leverage, if you know which questions unlock it.

The Real Math Behind Your Pharmacy Line

Most employers treat pharmacy spend as one number that moves up or down together. It doesn’t. Specialty drugs behave nothing like the rest of your Rx line, and averaging them together hides exactly where your money is going.

Pharmacy now runs roughly 23% of total healthcare cost, net of rebates, according to the 2026 Milliman Medical Index. That’s up from about 21% the year before, and it grew 14.8% while total plan cost grew 7.9%. The Business Group on Health puts it at 24% of employer healthcare dollars for 2024. Pharmacy isn’t a side conversation anymore. It’s a quarter of your plan.

Inside that bucket, one category is doing nearly all of the damage: specialty drugs. Biologics, injectables, infusions, and complex oral therapies for autoimmune disease, oncology, and rare conditions. A handful of members can single-handedly move your renewal. And in a soft market for medical trend, specialty is the one place carriers and PBMs can’t paper over with network discounts. It shows up raw.

So here’s the test. If your broker or PBM can’t walk you through which specific drugs and which specific members are driving your Rx trend, they aren’t doing analysis. They’re reading you a total.

Half Your Specialty Spend Isn’t on Your Pharmacy Report

Here’s a structural blind spot most employers have never had explained to them: a large share of specialty drug spend never appears on the pharmacy benefit at all. Drugs administered in a clinical setting, like infusions, injectables, and oncology therapies, get billed under the medical benefit, where they land in outpatient facility claims instead of pharmacy claims.

Prime Therapeutics’ 2025 Medical Pharmacy Trend Report estimates those medical-benefit drugs make up approximately 55% of specialty spend. Oncology alone accounts for 40.7% of commercial medical drug spend.

Milliman’s index confirms the mechanism from the other direction, noting that specialty drugs administered in outpatient settings “generate both a drug cost and a separate facility fee, compounding the cost impact.” That 23% pharmacy figure? It excludes those drugs. They’re sitting inside the 31% outpatient facility line.

The practical consequence is blunt. When your broker hands you a pharmacy report and says specialty is X% of your Rx spend, that report is describing roughly half the problem. The other half is buried in medical claims, unmanaged and usually unexamined, because the pharmacy team looks at pharmacy claims, the medical team looks at medical claims, and nobody owns the drug.

This Isn’t a Big Pharma Problem. It’s a Supply Chain Problem.

The biggest obstacle to controlling specialty drug cost usually isn’t the drug manufacturer. It’s the plumbing between the manufacturer and your plan.

The largest health insurers have spent the last decade vertically integrating, acquiring PBMs, specialty pharmacies, and provider groups so the same parent company touches the drug at every stage: negotiating the price, filling the prescription, and adjudicating the claim. Cigna and Express Scripts. CVS, Aetna, and Caremark. UnitedHealth and Optum Rx. Those aren’t partnerships. They’re the same balance sheet.

When one company profits at every link in that chain, there’s very little incentive to hand an employer a program that meaningfully reduces specialty spend. The savings would come out of their own pocket. That’s why specialty sourcing almost never surfaces inside a fully-insured carrier plan, a carrier-run level-funded plan, or an ASO arrangement tied to one of the big integrated PBMs.

It’s the same structural problem we mapped on the broker side in Exposing the Hidden Costs of Health Insurance Broker Commissions. Different link in the chain, identical mechanism: the party advising you on the spend is paid by the spend.

The Two Levers of Specialty Sourcing

Specialty sourcing is the practice of getting a member the same medication through a lower-cost legitimate channel before the plan pays retail for it. Strip away the marketing and it comes down to two levers. Every employer should understand both well enough to name them out loud at a renewal meeting.

Lever 1: Manufacturer assistance programs

Drug manufacturers run financial assistance programs for patients who meet eligibility criteria, largely based on household size and income relative to that household size. Done right, this routes a member’s specialty drug cost through the manufacturer’s own assistance dollars instead of your plan’s claims. Done wrong, or not at all, your plan pays full price for a drug the manufacturer would have subsidized.

The failure mode here is quiet. Nobody sends you a notice that a member qualified for help they never got. It surfaces mid-plan-year, if it surfaces at all, when someone finally checks eligibility on a six-figure annual drug cost that’s been running at full price the entire time.

Lever 2: International sourcing

When a member’s income is too high to qualify for assistance, the next lever is sourcing the same medication, from the same manufacturer in the same formulation through a verified pharmacy, from a tier-1 country such as Canada, the United Kingdom, Australia, or New Zealand, where the identical drug carries a fraction of the U.S. list price.

This is the backup play, not the primary one. But for the members it applies to, it’s often the difference between a renewal-moving claim and a manageable one.

Neither lever is exotic. Both require a PBM or advisor who has actually built the vendor relationships and will walk your claims data looking for who qualifies, rather than hoping you never ask.

Why This Is a Fiduciary Duty, Not a Cost-Cutting Tactic

If you sponsor a self-funded or level-funded plan, you’re a plan fiduciary. ERISA requires you to act prudently and solely in the interest of your participants when you spend plan assets. Most employers hear “fiduciary” and think about compliance paperwork. It’s worth thinking about it in terms of a single specialty claim instead.

Say a member is on a six-figure biologic. The manufacturer runs an assistance program that member qualifies for. Nobody checks. Your plan, funded by company dollars and employee contributions, pays the full amount for a year.

That’s not a missed savings opportunity. That’s plan assets spent on something the plan didn’t have to buy, because no one performed the review. Specialty sourcing done properly is how that duty gets discharged: every specialty claimant screened, every eligibility path checked, documented, and repeated annually.

The distinction that matters is how the program is built. Real specialty sourcing layers screening and advocacy on top of your existing coverage. The member stays covered the entire time. If assistance comes through, the plan saves. If it doesn’t, the drug is still paid for under the plan, exactly as written.

There are vendors in this market who do something different. They carve specialty drugs out of the plan document entirely and make coverage contingent on the member enrolling with a third party. That’s not specialty sourcing. That’s a coverage exclusion with a service wrapper, and it’s the version that creates exposure rather than discharging it.

You can tell them apart with one question, and it’s question five below.

Where Employers Get This Wrong

The mistake we see most often isn’t ignorance. It’s the reasonable assumption that the plan is “handling it” because nobody has raised a flag. Three patterns show up again and again.

Assuming your PBM is allowed to help

Employers renew with the same PBM year after year without asking whether that PBM is contractually permitted to bring in an independent specialty sourcing vendor. Many PBM contracts, especially ones bundled inside a carrier’s fully-insured or level-funded product, are written so outside vendors can’t touch the specialty spend at all. You aren’t being told no. You’re being told nothing, because the question never got asked.

Treating a large claimant as purely a stop-loss problem

When a member lands on a high-cost specialty drug, the reflex is to route it to stop-loss and move on. The first question should be whether that member has been screened before the claim ever reaches the reinsurance layer. Every dollar that hits your specific deductible is a dollar in your next renewal. It’s also the raw material for a laser. We covered how that plays out in Traps in Stop-Loss Coverage and How to Avoid Them.

Confusing wellness spending with cost containment

A steps challenge won’t move a plan where a few members on specialty drugs drive the majority of pharmacy trend. Population health matters over a ten-year horizon. It doesn’t fix a renewal. The dollars and the attention belong on the handful of claims actually doing the damage.

The 5 Questions to Force at This Renewal

Whether you’re self-funded, level-funded, or still fully insured, this is a conversation worth forcing 90 days before your renewal, not after the invoice arrives. Bring these five, in this order, and write down the answers.

1. Can we choose our own PBM, independent of the carrier? If the answer is no, you’ve found the ceiling on what you can do about specialty spend, and every other answer is academic.
2. Is our PBM contractually free to bring in an independent specialty sourcing vendor, or is that spend walled off? Ask to see the clause. “I believe so” is not a clause.
3. What’s our specialty spend across both the pharmacy and the medical benefit, as one number? Roughly half of it is billed as outpatient facility claims. An advisor who can only produce the pharmacy side can only manage the pharmacy side.
4. Has anyone screened our current specialty claimants for manufacturer assistance eligibility in the last twelve months? Not “could we.” Has anyone. A date and a name, or the answer is no.
5. If a member’s assistance application is denied, does the plan still cover the drug? This is the one that separates real specialty sourcing from a coverage carve-out dressed up as a program. The answer should be an immediate yes.

If your broker can’t answer those five with your actual claims data in front of them, you’re not getting a strategy. You’re getting a renewal number.

Employers exploring alternatives to a traditional fully-insured structure should also look at how self-funded health plans and level-funded health plans open the door to the independent PBM and sourcing arrangements a fully-insured plan simply won’t allow. And because specialty drugs are one piece of a larger problem, it’s worth reviewing your full pharmacy strategy alongside options like direct contracting, which attacks the same vertical-integration problem on the medical side of the ledger.

What This Looked Like for One 100-Life Employer

A 100-life St. Louis employer came to us carrying a Cigna PBM arrangement at $132 PMPM. Nobody had told them the number was high, because inside a bundled arrangement there’s nothing to compare it to.

We moved their pharmacy to SmithRx at $55 PMPM, a $77 PMPM reduction, or roughly $92,000 a year across 100 members. Separately, we replaced carrier-network percentage-off-billed-charges pricing with a direct contract with BJC.

Combined, those two moves took total plan spend down 28%.

Worth being precise about what that number is and isn’t. The 28% is the combined result of the pharmacy move and the direct contract, not either one alone. And those pharmacy savings came from changing the PBM relationship itself. Specialty sourcing is a separate layer that sits on top of a transparent PBM contract, not a substitute for having one.

That sequence isn’t an accident. You fix the contract first, then the sourcing. Doing it the other way around is how employers end up paying a vendor a percentage of savings they could have had outright.

Frequently Asked Questions

What counts as a specialty drug on an employer health plan?

Specialty drugs are high-cost medications that typically treat complex, chronic, or rare conditions: biologics, injectables, infused therapies, and complex oral drugs used in autoimmune disease, oncology, and rare disease. There’s no single legal definition. Each PBM maintains its own specialty list, which is one reason two plans can classify the same drug differently. What they share in practice is a cost per fill high enough that a few members materially change a plan’s trend.

What is specialty sourcing?

Specialty sourcing is the practice of obtaining a member’s specialty medication through a lower-cost legitimate channel before the plan pays retail price for it. The two main levers are manufacturer assistance programs, which route eligible members through the manufacturer’s own financial assistance dollars, and international sourcing from tier-1 countries, where the identical drug carries a fraction of the U.S. list price. Done properly, it layers on top of existing coverage rather than replacing it.

How much of my specialty drug spend is on the medical benefit instead of the pharmacy benefit?

Roughly 55%, according to Prime Therapeutics’ 2025 Medical Pharmacy Trend Report. Drugs administered in a clinical setting, like infusions, injectables, and oncology therapies, are billed under the medical benefit and appear as outpatient facility claims, not pharmacy claims. This is why a pharmacy report alone describes about half of an employer’s real specialty exposure.

Is specialty sourcing a fiduciary risk?

When it’s structured as advocacy layered on top of existing coverage, it’s the opposite. It’s how a plan fiduciary demonstrates that plan assets weren’t spent without review. The design that creates exposure is the one that excludes specialty drugs from the plan document and makes coverage contingent on enrolling with a third-party vendor. The distinguishing question is whether the plan still covers the drug if a member’s assistance application is denied.

Can a fully-insured employer do anything about specialty drug costs?

Less than a self-funded employer, but not nothing. In a fully-insured arrangement the carrier owns the pharmacy contract, so independent sourcing is generally unavailable. The realistic move is to evaluate whether a level-funded or self-funded structure fits. That structural change is what unlocks an independent PBM and the sourcing options that come with it.

How do I know if my PBM contract lets me bring in an outside specialty vendor?

Ask for the contract language, not a verbal answer. Look specifically for exclusivity provisions, carve-out restrictions, and any clause requiring specialty drugs to be dispensed through an affiliated specialty pharmacy. Bundled carrier arrangements frequently contain all three.

When should we start this conversation before renewal?

About 90 days out. Claims analysis takes time, PBM contracts have notice requirements, and any sourcing arrangement needs to be scoped before your contract locks for the next plan year. Starting after you receive the renewal number leaves you negotiating instead of designing.

Sources

• Pharmaceutical Strategies Group, 2026 Artemetrx State of Specialty Spend and Trend Report (2025 data)
• Milliman, 2026 Milliman Medical Index
• Business Group on Health, 2026 Employer Health Care Strategy Survey
• Prime Therapeutics, 2025 Medical Pharmacy Trend Report